Theranexus

Equities

ALTHX

FR0013286259

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:08:21 2024-04-26 am EDT			5-day change	1st Jan Change
1.135 ^EUR	+1.34%		+8.10%	+1.34%

Apr. 19	Theranexus: share price rises following promising trial results	CF
Mar. 11	Theranexus: CEO takes over as Chairman of the Board	CF

Theranexus Société Anonyme has completed an IPO in the amount of €20.962076 million.

October 25, 2017 at 12:00 am EDT

Theranexus Société Anonyme has completed an IPO in the amount of €20.962076 million. Security Name: Bearer Shares Security Type: Common Stock Securities Offered: 1,352,392 PriceRange: €15.5 Transaction Features: Sponsor Backed Offering

Latest news about Theranexus

Theranexus: share price rises following promising trial results	Apr. 19	CF
Theranexus: CEO takes over as Chairman of the Board	Mar. 11	CF
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024.	Jan. 10	CI
Theranexus: promising results in Batten disease	23-09-29	CF
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Theranexus SociÃ©tÃ© Anonyme announced that it has received â‚¬2.470412 million in funding	23-07-11	CI
Theranexus: share price rises on promising trials	23-06-14	CF
Theranexus: EMA positive on Phase 3 design	23-06-07	CF
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...	23-05-09
Erytech: renewed confidence in merger project	23-05-09	CF
Theranexus: FDA approval for Batten disease	23-05-09	CF
Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease	23-05-09	CI
Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-12	CI
Theranexus: good financial visibility for fiscal 2023	23-01-18	CF
Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease	23-01-05	CI
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-27	CI
Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-30	CI
Theranexus : to Begin Early-Stage Study of Rare Disease Drug	21-09-10	MT
Theranexus : Creates Drug Development JV; Stock Down4%	20-12-18	MT
Theranexus Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-17	CI
Theranexus to Present Latest Findings on the Role of Astroglial Connexins in the Efficacy of THN201 in Neurocognitive Disorders Linked to Alzheimer's Disease	19-03-26	CI
Certain Bearer Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 25-OCT-2018.	18-10-24	CI
Theranexus Société Anonyme has completed an IPO in the amount of €20.962076 million.	17-10-25	CI
Theranexus Société Anonyme has filed an IPO in the amount of €23.729247 million.	17-10-10	CI

Chart Theranexus

Duration

Period

More charts

Company Profile

Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.135 EUR

Average target price

4 EUR

Spread / Average Target

+252.42%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERANEXUS	+1.34%	9.4M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs